Logo
x

Search

Subscribe Now

BeiGene

BeiGene to Highlight Data from P-III (SEQUOIA) Study of Brukinsa in Combination with Venetoclax for CLL/SLL at EHA2024

BeiGene to Highlight Data from P-III (SEQUOIA) Study of Brukinsa in Combination with Venetoclax for CLL/SLL at EHA2024

  • June 14, 2024
The US FDA Grants Approval to BeiGene’s Tevimbra to Treat Advanced or Metastatic Esophageal Squamous Cell Carcinoma

The US FDA Grants Approval to BeiGene’s Tevimbra to Treat Advanced or Metastatic Esophageal Squamous Cell Carcinoma

  • March 15, 2024
BeiGene’s Brukinsa Receives the US FDA’s Accelerated Approval for the Treatment of Follicular Lymphoma (FL)

BeiGene’s Brukinsa Receives the US FDA’s Accelerated Approval for the Treatment of Follicular Lymphoma (FL)

  • March 8, 2024
BeiGene Reports Results from a Comparative Analysis of Brukinsa vs Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia (CLL)

BeiGene Reports Results from a Comparative Analysis of Brukinsa vs Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia...

  • March 1, 2024
BeiGene’s Tevimbra (tislelizumab) Receives CHMP’s Positive Opinion for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

BeiGene’s Tevimbra (tislelizumab) Receives CHMP’s Positive Opinion for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

  • February 27, 2024
Insights+: EMA Marketing Authorization of New Drugs in November 2023

Insights+: EMA Marketing Authorization of New Drugs in November 2023

  • December 29, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.